Conduit Pharmaceuticals Files 8-K on Shareholder Nominations
Ticker: CDTTW · Form: 8-K · Filed: Jul 1, 2024 · CIK: 1896212
| Field | Detail |
|---|---|
| Company | Conduit Pharmaceuticals Inc. (CDTTW) |
| Form Type | 8-K |
| Filed Date | Jul 1, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-nomination, corporate-governance, 8-k
TL;DR
Conduit Pharma (CP) filed an 8-K for shareholder nominations - board shakeup incoming?
AI Summary
Conduit Pharmaceuticals Inc. filed an 8-K on July 1, 2024, to report shareholder nominations pursuant to Exchange Act Rule 14a-11. The company, formerly known as Murphy Canyon Acquisition Corp. until November 30, 2021, is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This filing indicates potential changes or activism within Conduit Pharmaceuticals' shareholder base, which could influence the company's strategic direction or board composition.
Risk Assessment
Risk Level: medium — Shareholder nominations can signal activism or disputes, potentially leading to significant changes in company strategy or leadership.
Key Players & Entities
- Conduit Pharmaceuticals Inc. (company) — Registrant
- Murphy Canyon Acquisition Corp. (company) — Former company name
- July 1, 2024 (date) — Date of earliest event reported
- November 30, 2021 (date) — Date of name change
- Exchange Act Rule 14a-11 (regulation) — Subject of the filing
FAQ
What is the specific purpose of the shareholder nominations being reported?
The filing states the nominations are pursuant to Exchange Act Rule 14a-11, which relates to shareholder nominations of directors.
When was Conduit Pharmaceuticals Inc. formerly known by another name?
The company was formerly known as Murphy Canyon Acquisition Corp. until November 30, 2021.
In which state is Conduit Pharmaceuticals Inc. incorporated?
Conduit Pharmaceuticals Inc. is incorporated in Delaware.
What is the business address of Conduit Pharmaceuticals Inc.?
The business address is 4995 Murphy Canyon Road, Suite 300, San Diego, California.
What is the earliest event date reported in this 8-K filing?
The earliest event date reported is July 1, 2024.
Filing Stats: 557 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-07-01 16:30:39
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share CDT The Nasdaq
- $11.50 — of Common Stock at an exercise price of $11.50 CDTTW The Nasdaq Stock Market LLC
Filing Documents
- form8-k.htm (8-K) — 40KB
- 0001493152-24-025805.txt ( ) — 256KB
- cdt-20240701.xsd (EX-101.SCH) — 4KB
- cdt-20240701_def.xml (EX-101.DEF) — 26KB
- cdt-20240701_lab.xml (EX-101.LAB) — 36KB
- cdt-20240701_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 1, 2024 CONDUIT PHARMACEUTICALS INC. By: /s/ Dr. David Tapolczay Name: Dr. David Tapolczay Title: Chief Executive Officer